Clinical Trial Update: Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating temozolomide in patients with recurrent oligodendroglial brain tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oligodendroglioma

Drugs mentioned

• Temodar (Temozolomide)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Brain and Central Nervous System Tumors | Phase 2 | Status: COMPLETED